A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence

Addictive Behaviors

Volumn 36, Issue 3, 2011, Pages 217-221

  Kampman, Kyle M ^a   Dackis, Charles ^a   Pettinati, Helen M ^a   Lynch, Kevin G ^a   Sparkman, Thorne ^a   O'Brien, Charles P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Education and Clinical Center   (United States)

Author keywords

Acamprosate; Clinical trial; Cocaine; Placebo

Indexed keywords

ACAMPROSATE; BENZOYLECGONINE; PLACEBO;

ADDICTION SEVERITY INDEX; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COCAINE DEPENDENCE; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FLATULENCE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PATIENT COMPLIANCE; SKIN INFECTION; STATISTICAL ANALYSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; CENTRAL NERVOUS SYSTEM AGENTS; COCAINE; COCAINE-RELATED DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA; PILOT PROJECTS; TAURINE; TREATMENT OUTCOME;

EID: 78650910189     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2010.11.003     Document Type: Article

References (22)

1. Allgaier C., Franke H., Sobottka H., Scheibler P. Acamprosate inhibits Ca2+ influx mediated by NMDA receptors and voltage-sensitive Ca2+ channels in cultured rat mesencephalic neurones. Naunyn-Schmiedebergs Archives of Pharmacology 2000, 362(4-5):440-443.
2. Backstrom P., Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 2006, 31(4):778-786.
3. Backstrom P., Hyytia P. Involvement of AMPA/kainate, NMDA, and mGlu5 receptors in the nucleus accumbens core in cue-induced reinstatement of cocaine seeking in rats. Psychopharmacology 2007, 192(4):571-580.
4. Bell K., Duffy P., Kalivas P.W. Context-specific enhancement of glutamate transmission by cocaine. [Research Support, U.S. Gov't, P.H.S.]. Neuropsychopharmacology 2000, 23(3):335-344.
5. Bowers M.S., Chen B.T., Chou J.K., Osborne M.P.H., Gass J.T., See R.E., et al. Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats. Psychopharmacology 2007, 195(3):397-406.
6. Dahchour A., De Witte P. Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Progress in Neurobiology 2000, 60(4):343-362.
7. Dahchour A., De Witte P., Bolo N., Nedelec J.F., Muzet M., Durbin P., et al. Central effects of acamprosate: part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Research 1998, 82(2):107-114.
8. De Witte P., Littleton J., Parot P., Koob G., De Witte P., Littleton J., et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. [Research Support, Non-U.S. Gov't Review]. CNS Drugs 2005, 19(6):517-537.
9. Diggle P.J., Kenward M.G. Informative dropout in longitudinal data analysis (with Discussion). Applied Statistics 1994, 43:43-93.
10. First M., Spitzer R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
11. Assessment Manual for Psychopharmacology: Publication ADM 76-338 1976, US Department of Health Education and Welfare, Washington, DC. W. Guy (Ed.).
12. Kadden R., Carroll K.M., Donovan D., Cooney N., Monti P., Abrams D., et al. Cognitive Behavioral Coping Skills Manual 1992, vol. 3. U.S. Government Printing Office, Washington, DC.
13. Kampman K.M., Volpicelli J.R., McGinnis D.E., Alterman A.I., Weinrieb R.M., D'Angelo L., et al. Reliability and validity of the cocaine selective severity assessment. Addictive Behaviors 1998, 23(4):449-461.
14. Lee B., Platt D.M., Rowlett J.K., Adewale A.S., Spealman R.D. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. Journal of Pharmacology & Experimental Therapeutics 2005, 312(3):1232-1240.
15. McGeehan A.J., Olive M.F. The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine. British Journal of Pharmacology 2003, 138(1):9-12.
16. McGeehan A.J., Olive M.F. Attenuation of cocaine-induced reinstatement of cocaine conditioned place preference by acamprosate. Behavioural Pharmacology 2006, 17(4):363-367.
17. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the addiction severity index. Journal of Substance Abuse Treatment 1992, 9(3):199-213.
18. Rammes G., Mahal B., Putzke J., Parsons C., Spielmanns P., Pestel E., et al. The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology 2001, 40(6):749-760. 749-60,2001.
19. Sheehan D.V., Lecrubier Y., Harnett-Sheehan K., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998, 59(Suppl 20):22-33.
20. Somoza, E., Dyrenforth, S., Goldsmith, J., Mesinskis, J., & Cohen, M. (1995). In search of a universal drug craving scale. Paper presented at the Annual Meeting of the American Psychiatric Association.
21. Xi Z.X., Ramamoorthy S., Baker D.A., Shen H., Samuvel D.J., Kalivas P.W., et al. Research support, U.S. Gov't, P.H.S. Journal of Pharmacology & Experimental Therapeutics 2002, 303(2):608-615.
22. Zeise M.L., Kasparov S., Capogna M., Zieglgansberger W. Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. European Journal of Pharmacology 1993, 231(1):47-52.